In vitro activities of tedizolid compared with other antibiotics against Gram-positive pathogens associated with hospital-acquired pneumonia, skin and soft tissue infection and bloodstream infection collected from 26 hospitals in China
机构：[1]Department of Clinical Laboratory, Peking University People’s Hospital, Beijing 100044, PR China[2]Zhongshan Hospital Fudan University, Shanghai 200032, PR China[3]The First Hospital of China Medical University, Shenyang 110001, PR China[4]Shengjing Hospital of China Medical University, Shenyang 110004, PR China中国医科大学盛京医院[5]Beijing Hospital, Beijing 100730, PR China[6]Affiliated Xinan Hospital of Third Military Medical University, Chongqing 400038, PR China[7]First Affiliated Hospital of Kunming Medical University, Kunming 650032, PR China昆明医科大学附属第一医院[8]Shanxi Provincial People’s Hospital, Xi’an 710068, PR China陕西省人民医院[9]The First Teaching Hospital of Xinjiang Medical University, Urumqi 830054, PR China[10]Affiliated Puai Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, PR China[11]Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, PR China北京朝阳医院[12]The Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010000, PR China[13]The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, PR China[14]The First Affiliated Hospital of Anhui Medical University, Hefei 230022, PR China[15]The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510230, PR China[16]The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, PR China[17]General Hospital of Ningxia Medical University, Yinchuan 750004, PR China[18]Shandong Provincial Hospital, Jinan 250021, PR China[19]China-Japan Union Hospital of Jilin University, Changchun 130033, PR China吉林大学中日联谊医院[20]First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, PR China中山大学附属第一医院[21]Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai 200025, PR China[22]Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, PR China[23]Xijing Hospital, The Fourth Military Medical University, Xi’an 710032, PR China[24]Tianjin Medical University General Hospital, Tianjin 300052, PR China[25]The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, PR China[26]The First Affiliated Hospital, Zhejiang University, Hangzhou 310003, PR China浙江大学医学院附属第一医院
To evaluate the in vitro antimicrobial activities of tedizolid, linezolid and other comparators against clinically significant Gram-positive cocci isolates from hospital-acquired pneumonia (HAP), skin and soft tissue infection (SSTI) and bloodstream infection (BSI), 2140 nonduplicate isolates (23.7% isolated from HAP, 46.8% from SSTI and 29.5% from BSI) were consecutively collected in 26 hospitals in 17 cities across China during 2014. These pathogens included 632 methicillin-resistant Staphylococcus aureus, 867 methicillin-sensitive Staphylococcus aureus, 299 coagulase-negative Staphylococcus (CoNS), 104 Enterococcus faecalis, 99 Enterococcus faecium, 13 Streptococcus pneumoniae, 23 alpha-haemolytic Streptococcus and 103 beta-haemolytic Streptococcus. MICs of routine clinical antibiotics were determined by broth microdilution method according to the Clinical and Laboratory Standards Institute guidelines 2015. Tedizolid, linezolid, vancomycin, daptomycin, teicoplanin and tigecycline showed high in vitro activity against Gram-positive pathogens (>= 98.0% susceptible), and tedizolid exhibited four-to eight fold greater activity than linezolid against the pathogens tested, with MIC(90)s of methicillin-resistant Staphylococcus aureus, alpha-haemolytic Streptococcus and beta-haemolytic Streptococcus (0.25 vs 2 mu g ml(-1)); methicillin-sensitive Staphylococcusaureus, E. faecalis and E. faecium (0.5 vs 2 mu g ml(-1)); methicillin-resistant CoNS and methicillin-sensitive CoNS (0.25 vs 1 mu g ml(-1)); and Streptococcus pneumoniae (0.125 vs 0.5 mu g ml(-1)). Tedizolid MIC(90)s associated with different infections did not show significant differences, and the drug exhibited excellent activity against surveyed Gram-positive pathogens associated with HAP, SSTI and BSI, including linezolid-nonsusceptible strains. These data suggest that tedizolid could be an alternative to linezolid for the treatment of infections caused by Gram-positive organisms.
基金：
We thank all of the investigators for their participation in this study. We also thank the Highfield Communication (Oxford,UK) for language editorial support in preparation of this manuscript. This work was supported by a grant from Bayer HealthCare Pharma. The study was partly supported by the National Natural Science Foundation of China (nos 81371856 and 81471990) and the Beijing Natural Science Foundation (no. 7143185).
第一作者机构：[1]Department of Clinical Laboratory, Peking University People’s Hospital, Beijing 100044, PR China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Li Shuguang,Guo Yu,Zhao Chunjiang,et al.In vitro activities of tedizolid compared with other antibiotics against Gram-positive pathogens associated with hospital-acquired pneumonia, skin and soft tissue infection and bloodstream infection collected from 26 hospitals in China[J].JOURNAL OF MEDICAL MICROBIOLOGY.2016,65(10):1215-1224.doi:10.1099/jmm.0.000347.
APA：
Li, Shuguang,Guo, Yu,Zhao, Chunjiang,Chen, Hongbin,Hu, Bijie...&Wang, Hui.(2016).In vitro activities of tedizolid compared with other antibiotics against Gram-positive pathogens associated with hospital-acquired pneumonia, skin and soft tissue infection and bloodstream infection collected from 26 hospitals in China.JOURNAL OF MEDICAL MICROBIOLOGY,65,(10)
MLA：
Li, Shuguang,et al."In vitro activities of tedizolid compared with other antibiotics against Gram-positive pathogens associated with hospital-acquired pneumonia, skin and soft tissue infection and bloodstream infection collected from 26 hospitals in China".JOURNAL OF MEDICAL MICROBIOLOGY 65..10(2016):1215-1224
